Becton, Dickinson and Company (BDX) Stock forecasts
Argus has updated its outlook for Becton, Dickinson and Company (BDX), lifting its target price and raising EPS estimates for the medical equipment manufacturer. The report, authored by Senior Analyst David H. Toung, notes BD's operations across four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. The current stock price for BDX is $176.80.
Cardinal Health extends CVS deal. What it means for Cardinal Health stock
Cardinal Health has extended its pharmaceutical distribution agreement with CVS Health through June 30, 2032. The company also reaffirmed its fiscal year 2027 non-GAAP earnings per share guidance, projecting 13% to 15% growth. The Cardinal Health stock traded flat at EUR 202.90 in weekend trading after the announcement.
How CVS Deal Extension At Cardinal Health (CAH) Has Changed Its Investment Story
Cardinal Health extended its pharmaceutical distribution agreement with CVS Health until June 30, 2032, maintaining its current service scope and reaffirming its fiscal 2027 non-GAAP EPS growth guidance. This extension solidifies a key partnership, supporting Cardinal Health's long-term planning for specialty distribution expansion and mix shift towards higher-margin services. The upcoming fiscal 2027 Q1 results on November 5 will provide further insight into how this agreement fits into the company's guidance and capital allocation priorities.
Boston Scientific Corporation (BSX) Stock forecasts
This article provides an analyst report on Boston Scientific Corporation (BSX) by Morningstar. The report, dated October 2, 2026, highlights competitive pressures affecting key growth areas for the company, which specializes in less invasive medical devices. Debbie S. Wang, a Senior Equity Analyst, authored the report.
Cardinal Health, McKesson Extend CVS Distribution Deals to 2032
Cardinal Health and McKesson have extended their pharmaceutical distribution agreements with CVS Health through June 2032, securing their largest customer for an additional six years. Cardinal Health's deal is a binding letter of intent, while McKesson's is an agreement in principle, with definitive contracts still pending. These extensions are significant as CVS Health represents a substantial portion of both distributors' revenues, accounting for 28% of Cardinal Health's FY2026 revenue and approximately 24% of McKesson's consolidated revenues for the same period.
Cardinal Health agrees to extend CVS deal: Cardinal Health stock gains 1.33 percent
Cardinal Health has extended its pharmaceutical distribution agreement with CVS Health until June 30, 2032, providing long-term volume security. The company reaffirmed its fiscal year 2027 non-GAAP earnings per share growth guidance of 13% to 15%. This announcement led to a 1.33% gain in Cardinal Health's stock price, with shares trading at EUR 206.35.
Becton, Dickinson and Company (BDX) Stock Forecasts
Argus has updated its outlook on Becton, Dickinson and Company (BDX), lifting its target price and raising EPS estimates for the medical equipment manufacturer. Headquartered in Franklin Lakes, NJ, BD operates through four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. The report, dated October 1, 2026, was authored by David H. Toung, a Senior Analyst specializing in Medical Devices & Healthcare Services.
CVS renews as Cardinal Health’s largest customer through 2032
Cardinal Health Inc. has secured an early renewal of its contract with its largest customer, CVS, extending their distribution deal through 2032. CVS accounts for over a quarter of Cardinal Health's sales and has added five years to the previous agreement. This renewal highlights the continued strong business relationship between the two healthcare giants.
AbbVie vs. Bristol Myers Squibb: A Clash Between Growth Premium and Value Trap
This article compares AbbVie (ABBV) and Bristol Myers Squibb (BMY), highlighting the dilemma investors face between AbbVie's growth premium and Bristol Myers' perceived value trap. AbbVie shows strong revenue growth driven by immunology but has a high valuation, while Bristol Myers Squibb, despite a lower valuation, faces legal challenges and patent expiry risks. The article examines their financial profiles, risks, and outlooks for 2026, suggesting AbbVie is a better long-term investment even at a premium.
Palvella Therapeutics Inc (PVLA-Q) Stock Price and News
This article provides stock information and news headlines for Palvella Therapeutics Inc. (PVLA-Q). It includes real-time stock data, analyst ratings, earnings call transcripts, and insights into the company's progress with its QTORIN product and Nasdaq uplisting. Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on rare genetic skin diseases.
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
This article compares AbbVie (ABBV) and Bristol Myers Squibb (BMY) as investment options for 2026, highlighting their financial profiles, growth drivers, and risk factors. AbbVie is seen as a higher-growth stock with new immunology drugs, while Bristol Myers Squibb offers a significant valuation discount but faces litigation and patent expiration challenges. The author recommends AbbVie for long-term investors despite its higher price, anticipating strong growth in net income.
Cardinal Health rises on extended CVS distribution deal By Investing.com
Cardinal Health Inc. shares increased by 3.7% after the company announced an extension of its drug distribution agreement with CVS Health through June 2032. This agreement maintains the current scope of distribution services and led Cardinal Health to reaffirm its fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth, or $12.40 to $12.60, along with its long-term non-GAAP EPS growth rate guidance. The company, a major pharmaceutical distributor, will provide further updates during its upcoming first-quarter earnings call.
One profession with endless impact: Celebrating pharmacists
This article celebrates the impactful role of pharmacists, highlighting that their work extends far beyond dispensing medication. Pharmacists are crucial in preventing hospitalizations, educating patients, and advocating for patient safety, leveraging science, problem-solving, and compassion to make a meaningful difference in individuals' health journeys. The piece emphasizes their accessibility and evolving role within healthcare, particularly across CVS Health.
Cardinal Health, McKesson Extend Distribution Pacts With CVS Through 2032
Cardinal Health and McKesson have both extended their pharmaceutical distribution agreements with CVS Health through mid-2032. Both companies reaffirmed their fiscal 2027 adjusted EPS guidance and long-term growth targets, with McKesson's shares rising 4.4% on the news. These agreements secure significant revenue streams for the distributors and provide stability in the drug distribution landscape.
Is Cardinal Health (CAH) Cheap As Its CVS Deal Extension Locks In Revenue Visibility?
Cardinal Health recently extended its distribution agreement with CVS Health through June 2032, securing long-term revenue visibility. Despite this, its share price has seen a recent pullback, leading some analysts to consider it 18% undervalued with a fair value estimate near $270.94. The company's valuation is seen as mixed, with a P/E ratio higher than the industry average but potentially justified by a shift towards higher-margin services.
McKesson Extends CVS Pharmaceutical Distribution Agreement Through 2032
McKesson Corp. has extended its pharmaceutical distribution agreement with CVS Health through June 2032, securing a partnership that has spanned over 25 years. This extension provides McKesson with greater visibility into a significant customer relationship as it reshapes its portfolio around pharmaceutical distribution and specialty care. Cardinal Health also announced a similar extension with CVS Health, highlighting CVS's strategy to ensure continuity in its pharmaceutical supply chain with major distributors.
Cardinal Health Extends CVS Pharmaceutical Distribution Deal Through 2032
Cardinal Health has extended its pharmaceutical distribution agreement with CVS Health through June 30, 2032. This extension secures Cardinal Health's largest customer, which accounted for 28% of its fiscal 2026 revenue, providing long-term stability as Cardinal Health invests significantly in modernizing its pharmaceutical distribution network, including new facilities and automation. For distributors, this highlights the importance of securing major national accounts to ensure certainty for operational decisions.
Why Is Cardinal Health and McKesson Stock Trading Higher Today - CVS Health (NYSE:CVS), McKesson (NYSE:MC
Cardinal Health (NYSE: CAH) and McKesson Corporation (NYSE: MCK) both saw their stock trading higher after extending their pharmaceutical distribution agreements with CVS Health (NYSE: CVS) through June 2032. Cardinal Health reaffirmed its fiscal year 2027 adjusted earnings growth guidance and long-term EPS growth rate, while McKesson reiterated its fiscal 2027 adjusted earnings outlook and long-term EPS growth rate. This comes as Aetna, a CVS Health subsidiary, expands its prior authorization bundles for cancer treatments.
Investigation launched into LENZ Therapeutics over possible securities fraud after weak sales report.
Pomerantz LLP has initiated an investigation into LENZ Therapeutics following its weaker-than-expected Q2 2026 results, which showed flat organic sales for its VIZZ eye drop product and revenue primarily from one-time licensing deals. This led to a downgrade by Bank of America and a sharp drop in LENZ's stock price. The investigation will determine if LENZ and its executives engaged in securities fraud or unlawful practices, potentially paving the way for legal action and compensation for affected shareholders.
Replimune CEO and CFO sued for allegedly misleading investors on FDA study concerns, causing stock to plunge.
Replimune Group's CEO Sushil Patel and CFO Emily Hill are facing a securities class action lawsuit for allegedly misleading investors regarding unresolved FDA study-design issues related to their RP1 biologics license resubmission. The lawsuit claims they falsely presented the resubmission as complete, leading to a significant drop in Replimune's stock price from $10.73 to $1.70. Investors who purchased shares during this period may be eligible to recover losses, with the lead plaintiff application deadline set for October 5, 2026.
Cardinal Health Extends CVS Health Pharmaceutical Distribution Agreement Through 2032
Cardinal Health has extended its pharmaceutical distribution agreement with CVS Health through June 30, 2032. The extended agreement maintains the existing scope of distribution services. Cardinal Health also reaffirmed its non-GAAP earnings guidance for fiscal 2027, projecting 13% to 15% growth, and its longer-term guidance of 12% to 14% growth.
Cardinal Health to extend pharmaceutical distribution agreements with CVS Health
Cardinal Health has signed a binding Letter of Intent to extend its pharmaceutical distribution agreement with CVS Health through June 30, 2032. This continuation reflects the existing scope of services and reaffirms Cardinal Health's fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth ($12.40 to $12.60) and a long-term non-GAAP EPS growth rate of 12% to 14%. The company values its long-standing partnership with CVS Health and anticipates providing further updates during its upcoming first-quarter earnings call on November 5, 2026.
Cardinal Health Extends Distribution Agreement With CVS Health, Backs Fiscal Year Guidance
Cardinal Health has extended its drug distribution agreement with CVS Health through June 30, 2032. The company also reaffirmed its fiscal year guidance, expecting adjusted earnings per share to grow by 13% to 15% this fiscal year and 12% to 14% in the long term. This extension ensures Cardinal Health will continue to supply pharmaceuticals to CVS Health's pharmacies.
CVS Health and Cardinal Health (CAH) have a binding letter to extend drug distribution.
Cardinal Health has signed a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 30, 2032. The company also reaffirmed its fiscal year 2027 non-GAAP EPS guidance of $12.40 to $12.60, representing 13% to 15% growth, and its long-term non-GAAP EPS growth guidance of 12% to 14%. Further updates are expected during Cardinal Health's first-quarter earnings call on November 5, 2026.
Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health
Cardinal Health has entered into a binding Letter of Intent to extend its pharmaceutical distribution agreement with CVS Health until June 30, 2032. This extension maintains the current scope of distribution services and reaffirms Cardinal Health's fiscal year 2027 non-GAAP EPS guidance and long-term growth rates. The company values its partnership with CVS Health and anticipates providing further updates during its upcoming first-quarter earnings call.
Cardinal Health to report Q1 fiscal 2027 results on Nov 5 before NYSE opens
Cardinal Health (CAH) is scheduled to announce its first-quarter fiscal year 2027 financial results on November 5, before the New York Stock Exchange opens, followed by a webcast. This announcement is crucial for investors monitoring the company's performance and outlook in the healthcare distribution sector. As of October 1, 2026, CAH shares trade at USD 222.25 on Pluang, reflecting investor interest with all Pluang orders being buys ahead of the earnings release.
Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5
Cardinal Health (CAH) is scheduled to announce its first-quarter results for fiscal year 2027 on November 5. The article notes that this news item consists only of a headline with no further details provided.
Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health
Cardinal Health announced a binding Letter of Intent to extend its pharmaceutical distribution agreement with CVS Health until June 30, 2032. This extension reflects the continuation of Cardinal Health's current distribution services scope. The company also reaffirmed its fiscal year 2027 non-GAAP EPS growth guidance of 13% to 15% and its long-term non-GAAP EPS growth rate guidance of 12% to 14%.
Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5
Cardinal Health (NYSE: CAH) is scheduled to release its first-quarter financial results for fiscal year 2027 on November 5, before the market opens. The company will host a webcast at 8:30 a.m. Eastern to discuss these results, with presentation slides and a replay available on its Investor Relations page. Cardinal Health is a leading distributor of pharmaceuticals and medical products, and a provider of various healthcare services.
How Investors May Respond To McKesson (MCK) Raised 2027 EPS Guidance
McKesson (MCK) recently increased its fiscal 2027 adjusted EPS guidance, driven by strong performance in its Oncology & Multispecialty and Prescription Technology Solutions segments. This update suggests that the company's focus on specialty distribution, oncology services, and technology-enabled platforms is effectively offsetting margin pressures in its traditional drug distribution business. Analysts are now factoring in higher earnings power from these areas, projecting revenue growth of 6.9% annually and an increase in profit margins, along with significant share buybacks contributing to a higher EPS by 2029.
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Bristol Myers Squibb and Eli Lilly and Co. as healthcare stock investments for 2026, highlighting their differing investment profiles. Bristol Myers Squibb is presented as a deep-value dividend payer with an established but maturing portfolio, facing patent expirations and regulatory pressures. Eli Lilly is depicted as a high-growth pharmaceutical company driven by breakthroughs in metabolic treatments like GLP-1 drugs, with strong revenue growth and a more conservative debt profile. The author ultimately recommends Eli Lilly due to its significant growth potential and innovative pipeline.
Cardinal Health stock after-hours at EUR 197.65: plus 0.10 percent versus Lang & Schwarz prior close
Cardinal Health's stock traded at EUR 197.65 after-hours on September 30, 2026, marking a 0.10 percent increase from its prior close at Lang & Schwarz. The company's annual meeting is scheduled for November 12, 2026, where shareholders will vote on director nominees, executive compensation, and the independent auditor. Fiscal year 2026 results show significant growth with revenue of USD 254.2 billion and increased GAAP and non-GAAP operating earnings and EPS.
Cardinal Health stays a Buy with strong FY2026 results and promising FY2027 earnings growth guidance.
Cardinal Health (CAH) has reported strong fiscal year 2026 results, including significant revenue growth, gross margin increase, and doubled free cash flow, leading analysts to maintain a "Buy" rating. The company also provided promising FY2027 guidance with projected non-GAAP EPS growth of 13-15%, driven by improvements across its segments. Despite thin margins and higher liabilities, its valuation is considered reasonable, though macroeconomic and regulatory risks persist.
Total debt per share of Cardinal Health, Inc. – HAN:CLH
This page provides financial information for Cardinal Health, Inc. (CLH) on the Hannover Stock Exchange, specifically focusing on the "Total debt per share" metric. The content emphasizes that this data is "Made by humans" and sources its market and reference data from ICE Data Services and FactSet, respectively. The article itself does not present the actual debt per share value but rather highlights its availability.
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Bristol Myers Squibb (BMY) and Eli Lilly (LLY), two major healthcare stocks, to determine which is a better investment in 2026. BMY is presented as a deep-value dividend payer with a maturing drug portfolio and strong free cash flow, while LLY is characterized as a high-growth pharmaceutical juggernaut driven by its metabolic and weight-loss treatments. The analysis concludes that despite BMY's lower valuation, LLY's explosive growth potential from its GLP-1 drugs makes it the more attractive buy.
Cardinal Health stock after-hours at EUR 195.25: plus 0.89 percent
Cardinal Health's stock rose 0.89 percent after-hours to EUR 195.25 on September 29, 2026. The company announced its virtual annual meeting for November 12, 2026, where shareholders will vote on director nominees, executive compensation, and the independent auditor. Fiscal year 2026 saw strong performance with revenues up 14 percent and GAAP operating earnings up 15 percent.
Red Robin Gourmet Burgers (NASDAQ:RRGB) Stock Crosses Above Two Hundred Day Moving Average - Here's Why
Red Robin Gourmet Burgers (NASDAQ:RRGB) stock recently crossed above its 200-day moving average, trading at $7.46 compared to the average of $5.92. This comes after the company reported strong Q1 earnings, with EPS of $0.12 and revenue of $277.64 million, surpassing analyst expectations. Despite mixed analyst ratings, the stock holds a consensus "Hold" rating with an average price target of $8.33, and institutional investors own a significant 84.04% stake.
Cardinal Health stock follows 14 percent fiscal revenue growth
Cardinal Health's stock performance follows a strong fiscal year 2026, with revenue increasing by 14 percent to USD 254.2 billion. The company provided an optimistic fiscal 2027 adjusted EPS outlook of 13 percent to 15 percent, exceeding its long-range target. Analysts maintain a "Moderate Buy" consensus with a price target significantly above the current stock price, driven by growth in specialty revenue and strategic acquisitions.
Cardinal Health (CAH): Buy, Sell, or Hold Post Q2 Earnings?
Cardinal Health (CAH) has gained 6.8% in the last six months but lagged the S&P 500's 22.1% return. Despite its large scale and strong long-term EPS growth, concerns arise from decelerating revenue growth. The article suggests that CAH's positive attributes outweigh the negatives, and it trades at an attractive 17.6x forward P/E.
DataMeds AI Launches Health Lives Here App Focused on GLP-1 Telehealth and Pharmacy Services
DataMeds AI, in partnership with Tollo Health, has launched the "Health Lives Here" mobile application. This platform integrates GLP-1 telehealth services, pharmacy fulfillment, nutritional products, and health tracking, initially targeting patients using GLP-1 receptor agonist medications. The company plans to expand its services to include Long COVID and cancer patients, and intends to build a network with Corexa Health's independent pharmacies, beginning with a location in Concord, North Carolina.
Cardinal Health stock at USD 220.22 on September 25, 2026
Cardinal Health stock was last traded at USD 220.22 on September 25, 2026, down 1.08 percent from the previous session. Management described fiscal 2027 growth as a continuation of fiscal 2026 performance at more normalized rates, highlighting strong performance across all five operating segments in fiscal 2026. Pharmaceutical distribution remains central, with specialty, BioPharma Solutions, at-home care, nuclear medicine, and logistics identified as key growth areas.
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors looking at 2026. AbbVie is transitioning its focus to newer immunology drugs, while Pfizer is pursuing aggressive acquisitions in oncology and metabolic assets to counter post-pandemic revenue declines and upcoming patent expirations. While both offer significant dividends, Pfizer appears to be the more undervalued stock based on current valuation metrics, despite AbbVie's promising pipeline.
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors in 2026, analyzing their financial performance, product pipelines, and risk profiles. While AbbVie is transitioning from its Humira era with new immunology leaders, Pfizer is focusing on oncology and metabolic assets through acquisitions, navigating post-pandemic changes and patent expirations. The author ultimately suggests Pfizer is currently undervalued despite AbbVie's promising pipeline, due to Pfizer's lower valuation metrics and recent growth in its oncology business.
McKesson (MCK) Lifted Its Guidance, Is The Stock Still 11% Undervalued?
McKesson (MCK) recently raised its full-year adjusted EPS guidance, leading to investor reassessment despite a recent share price dip. While the stock has seen strong long-term gains, short-term momentum has cooled, prompting questions about its current valuation. Analysts, based on a "most followed view," suggest McKesson is still 11% undervalued, with a fair value of $980.73, driven by its focus on oncology and access platforms.
Cardinal Health Inc. stock underperforms Friday when compared to competitors
Cardinal Health Inc. (CAH) stock declined by 1.08% on Friday, closing at $220.22, despite an overall positive trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains. The company's stock is currently trading 14.74% below its 52-week high achieved on August 11th.
What Cardinal Health Stock's Specialty Push Means For Shareholders
Cardinal Health is shifting its focus towards specialty pharmaceuticals and higher-value healthcare services, including its role in the expanding medical textile sector. While this strategy aims to boost earnings and margins, investors need to monitor execution risk, input costs, and potential quality control issues. Analysts project significant revenue and earnings growth by 2029, though fair value estimates vary widely among investors.
Cardinal Health stock heads into the open after a 0.4 percent gain
Cardinal Health stock saw a 0.4 percent gain on September 24, 2026, closing at USD 178.42, while the Nasdaq Composite fell 1.1 percent. This performance marked a 1.5 percentage point outperformance for Cardinal Health compared to the reference index. The healthcare sector generally outperformed, with economic data like durable goods orders and consumer sentiment expected to influence the market on September 25, 2026.
Cardinal Health stock gains 1.47 percent on fiscal growth
Cardinal Health stock saw a 1.47 percent increase on the NYSE, reaching USD 224.52, following a strong fiscal year 2026 with revenues of USD 254.2 billion, up 14 percent. The company issued adjusted EPS guidance of USD 12.40 to USD 12.60 for fiscal 2027, anticipating continued growth. Despite mixed quarterly results, the company's operating execution and specialty growth are highlighted as key drivers for the upcoming fiscal year.
Danaher Corporation (DHR) stock price, news, quote and history - Yahoo Finance
This Yahoo Finance page provides a summary of Danaher Corporation (DHR) stock information, including its current price, market status, and a compilation of recent news articles from various financial outlets. The news highlights analyses of DHR's valuation, growth prospects in biotechnology and label-free detection, and comparisons with other healthcare stocks like Cardinal Health and Medtronic. It also touches upon factors influencing its stock performance, such as dividend reaffirmation and segment strength.
Cardinal Health vs. McKesson: Which Healthcare Stock Is Better?
This article compares Cardinal Health (CAH) and McKesson (MCK), two major players in U.S. pharmaceutical distribution. While both are positioned for growth and leverage specialty pharmaceuticals and technology, Cardinal Health shows stronger earnings momentum, better valuation, and a more favorable estimate revision trend. McKesson, despite its scale and specialty services, exhibits less valuation differentiation and a weaker momentum score.
